Status:
UNKNOWN
Impact of CYP3A4*1G Polymorphism on Non-analgesic Effects of Fentanyl in Chinese Han Patients
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Yichang Humanwell Pharmaceutical Co., Ltd., China
Conditions:
Fentanyl
Eligibility:
FEMALE
18-45 years
Brief Summary
Purpose: This study aimed to investigate the impact of CYP3A4\*1G genetic polymorphism on non-analgesic effects of fentanyl in Chinese Han patients. Methods: 200 patients receiving elective surgery un...
Eligibility Criteria
Inclusion
- American Society of Anesthesiologists GradeⅠ-II,Patients undergo elective surgery for benign Reproductive diseases (including laparoscopic ovarian cyst removal, laparoscopic tubal ligation, laparoscopic tubal drainage, laparoscopic salpingoplasty, etc.) or breast disease.
- Aged 18-45 years
- Body Mass Index 18-25kg/m2,body weight 40-65 kilograms
- Agreed to participate the research
Exclusion
- Difficult airway
- upper respiratory tract infection within 2 weeks
- history of allergy or long-term use of propofol and opioids
- self-rating anxiety scale before operation indicates anxiety
- pregnancy or lactation.
Key Trial Info
Start Date :
March 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 20 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03869346
Start Date
March 10 2019
End Date
May 20 2021
Last Update
September 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044